Galecto, Inc.
GLTODrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
GB1211
Non-Small Cell Lung Cancer
GB2064
Myelofibrosis
GB0139
Idiopathic Pulmonary Fibrosis (IPF)
Inhaled TD139
Idiopathic Pulmonary Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB1211 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
GB2064 | Phase 2 | Myelofibrosis | - | - |
GB0139 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
Inhaled TD139 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Frequently asked questions
What is in Galecto, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Galecto, Inc.'s (GLTO) pipeline across Phase 2. Its lead program is GB1211 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galecto, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galecto, Inc. (GLTO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLTO biotech catalysts?→
Add GLTO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galecto, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.